ZOLACOS

This brand name is authorized in Australia, New Zealand.

Active ingredients

The drug ZOLACOS contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 0F65R8P09N - GOSERELIN
 

Goserelin is a synthetic analogue of naturally occurring LHRH. On chronic administration goserelin results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females.

 
Read more about Goserelin
2
UNII A0Z3NAU9DP - BICALUTAMIDE
 

Bicalutamide is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition.

 
Read more about Bicalutamide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
L02AE Gonadotropin releasing hormone analogues L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents
Discover more medicines within L02AE

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 9064C, 9065D, 9066E
NZ Medicines and Medical Devices Safety Authority 13536, 13537

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.